Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This phase II study will be conducted in two parts at the same time, with a 21-day treatment
cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death,
initiation of new anti-tumor treatment or loss of follow-up.